ArticleLiver cancer2019
Surrogacy of Time to Progression for Overall Survival in Advanced Hepatocellular Carcinoma Treated with Systemic Therapy: A Systematic Review and Meta-Analysis of Randomized Controlled Trials.
Article in Liver cancer, 2019. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 17 papers, 2 of them syntheses that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
17 citing papers in PubMed, 2 syntheses or guidelines pooled it.
- Surrogacy of one-year survival for overall survival in advanced hepatocellular carcinoma.BMC cancer · 2024Pooled it
- Clinical benefits of PD-1/PD-L1 inhibitors in advanced hepatocellular carcinoma: a systematic review and meta-analysis.Hepatology international · 2020Pooled it
- Outcomes of early-stage hepatocellular carcinoma patients treated by resection or ablation: real-life data from the French Administrative Health Care database.Journal of liver cancer · 2026Article
- Reframing Post-Hepatectomy Liver Failure as a Determinant of Post-Recurrence Survival in HCC.Journal of hepato-biliary-pancreatic sciences · 2026Article
- Evaluation of surrogate endpoints in phase III randomized control trials of advanced hepatocellular carcinoma treated with immune checkpoint inhibitors.European journal of clinical pharmacology · 2025Article
- Comprehensive genomic profiling for advanced hepatocellular carcinoma in clinical practice.Hepatology international · 2025Article
- Article
- Association Between Immune-Related Adverse Events and Survival in Patients with Hepatocellular Carcinoma Treated With Atezolizumab Plus Bevacizumab.The oncologist · 2023Article
- The Evolving Scenario in the Assessment of Radiological Response for Hepatocellular Carcinoma in the Era of Immunotherapy: Strengths and Weaknesses of Surrogate Endpoints.Biomedicines · 2022Review
- Evolution of Survival Impact of Molecular Target Agents in Patients with Advanced Hepatocellular Carcinoma.Liver cancer · 2022Article
- Comparative study between sorafenib and lenvatinib as the first-line therapy in the sequential treatment of unresectable hepatocellular carcinoma in a real-world setting.JGH open : an open access journal of gastroenterology and hepatology · 2022Article
- Skeletal Muscle Volume Is an Independent Predictor of Survival after Sorafenib Treatment Failure for Hepatocellular Carcinoma.Cancers · 2021Article
- Comparison of efficacy outcomes of anticancer drugs between Japanese patients and the overall population.International journal of clinical oncology · 2021Article
- Primary Treatment with Molecular-Targeted Agents for Hepatocellular Carcinoma: A Propensity Score-matching Analysis.Hepatology communications · 2020Article
- Post-Progression Treatment Eligibility of Unresectable Hepatocellular Carcinoma Patients Treated with Lenvatinib.Liver cancer · 2020Article
- Co-targeting p53-R249S and CDK4 synergistically suppresses survival of hepatocellular carcinoma cells.Cancer biology & therapy · 2020Article
- Insights into the success and failure of systemic therapy for hepatocellular carcinoma.Nature reviews. Gastroenterology & hepatology · 2019Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
11 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Time to progression (TTP) is widely used as the endpoint in early-phase trials of advanced hepatocellular carcinoma (HCC). However, the relevance of using TTP as a surrogate marker for overall survival (OS) in pivotal trials remains uncertain. The PubMed database and ASCO Meeting Library were searched for reports of randomized controlled trials that investigated patients with advanced HCC, included data for both OS and TTP, and were launched between 2009 and 2016. The correlation between hazard ratios (HRs) for TTP and OS was determined using weighted linear regression. Correlations between median OS and TTP, and between median OS and postprogression survival (PPS), defined as the period obtained by subtracting the median TTP from the median OS, were also evaluated. The database search yielded 24 trials with 50 arms. Overall, TTP HR correlated with OS HR (
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.